1. Prototype Serial Zero VPEPN/H-201
Research Project
“Nuclear Magnetic Resonance Device”
Prototype Serial Zero VPEPN/H-201
Apparatus and corresponding Method which integrates the quantified diagnosis mode as well as selective and specialized therapy mode through the use of
Nuclear Magnetic Resonance technology for
Cure cancer and HIV/Aids
Principal inventor: Ing. Lázaro Eusebio Hernández Pérez
Patent holder : MRI-DT, S.A. de C.V.

2. Proposal main objectives Enable Nuclear Magnetic Resonance
apparatus for:
1.- Contributing with a quantified diagnostic in values of resonance frequencies.
2.- Emmitt specific radiation for a selective and specialized therapy

3. Acreditation in the National Registration of Scientific and Technological Institutions and Companies
MRI-DT, SA de CV - RENIECYT / CONACYT

4. Patent granted in United States

5. Patent granted in MEXICO

6. Patent granted in South Korea

7. Patent granted in Israel

8. Patent granted in Europe “EPO”

9. Patent granted in
Republic of China

10. Intellectual property
National phases
1. USA (Granted in June/2008)
2. Mexico (Granted in August/2008)
3. South Korea (Granted in October/2009)
4. Israel (Granted in January/2011)
5. European Patent Office “EPO”
(Granted in November/2011)
Germany, England, France, Netherlands,
Switzerland , Italy and Spain
6. China (Granted in December/2012)
7. Canada
8. Japan

11. Participant Institution
MRI-DT, S.A. de C.V.

12. MRI-DT / “CTB” & “UPM” PROJECT´S TITLE
There is a contract (CONCLUDED) to perform the “R&D” between MRI-DT and the Polytechnic University of Madrid “UPM”
Center for Biomedical Technology “CTB”
PROJECT´S TITLE
“Study the viability of a system of
hyperthermia induction in cancerous cells
through Hydrogen
Nuclear Magnetic Resonance”

13. Nuclear Magnetic Resonance Systems
Used only for diagnose
Functional Scheme 16 13 14 15 10 9 17 19 20 21 23 24 22 11 12 1 3 2 4 6 7 5 27 8

14. Conventional image and respective spectra obtained via Nuclear Magnetic Resonance

15. Spectral differentation through NMR of different types of cerebral pathologies

16. 25 26 18 MNR Prototype Serial Zero VPEPN/H-201
Quantitative diagnosis in values of resonance frequecies
Hardware Incorporated 8 1 J D H / 2 3 I 6 A X 25 26 28
57LY/20VI
78LY-LE/24VI 18 22 2 3 2 4 25 26 1 1 3 2 27 4 5 6 18 11 7 8 2 1 2 1 9 17 17 9 1 7 11 12 1 3 1 4 1 5 16 1 12 12

17. Tridimensional spectra of the pathology, showing the area of therapeutic interest which will be the “target” of our therapy

18. or from the Area of therapeutic interest of the same.
Tridimensional spectra of the area of therapeutic Interest of the pathology, overlapped in the matrix of frequencies
Only by the previous contrasting, is that we can obtain the exact and personalized value of resonance frequency that is specific of a pathology,
or from the Area of therapeutic interest of the same.

19. 18 16 NMR Prototype Serial Zero VPEPN/H-201
Selective and specialized therapy
Modified Hardware 18
78LY-LE/24VI 28
57LY/20VI 8 1 J D H / 2 3 I 6 A X 25 26 16 10 13 4 2 4 3 22 27 1 1 3 2 4 5 6 18 11 7 8 2 1 2 1 9 17 17 9 1 7 11 12 13 1 4 1 5 16 10 12 12

20. Patent radiation proposal Application main criteria
The RF applied through NMR complies with the therapeutic objective in a specialized and selective way
ENERGY CONTRIBUTION
Due to the use of a particular sequence of pulses to the (s) selected RF (s) to be (s) identified as of therapeutic interest, this therapy does NOT cause harmful secondary effects.

21. Conventional Radiotherapies Vs Patent´s Radiotherapy
Patent Radiotherapy
Ionizing Radiations
Non-Ionizing Radiations
Nuclear Magnetic Resonance
Cobalt therapy
Linear accelerator
Gamma knife
Brachytherapy
Etc.
Prototype Serial Zero VPEPN/H-201

22. Prototype Serial Zero VPEPN/H-201
Quantitative Diagnosis in values of resonance frequecies
Selective and Specialized Therapy 16 10 13 4 2 4 3 22 27
78LY-LE/24VI 28
57LY/20VI 18 8 1 J D H / 2 3 I 6 A X 25 26 1 1 3 2 4 5 6 18 11 7 8 2 1 2 1 9 17 17 9 1 7 11 12 13 1 4 1 5 16 10 12 12

23. MRI-DT, S.A. de C.V. Corporative Typology
The business model of MRI-DT, S.A. de C.V. is highly leveraged in KNOWLEDGE, own for the type of Open Innovation and Global 360 market approach suggested by Mr. Henry Chesbrough, father of the "Open Innovation".
Such type of enterprises are able to generate high revenue without deploying vast armies of staff and/or billions of dollars in physical assets... With an impressive business model built around: key technologies (as it is precisely the case of our scientific proposal) and their respective intellectual property.

24. Viability criteria Scientific Technical Commercial
The application of the physical principle in which the patent is
based, is provable in a theoretical and an experimental level
Technical
There are existing features (Hardware) in the market today
to fully implement it in a practical way
Commercial
The high demand for this NEW technological proposal
is properly identified

25. OF THE PATENT TECHNOLOGY
SELECTIVITY
OF THE PATENT TECHNOLOGY
OVER 95% EFFECTIVENESS
WITHOUT
COLLATERAL DAMAGES

26. Investment comparative for “R&D”
GENERAL ELECTRIC HEALTH CARE
Year
Business Volume
(Millions of Dollars)
“R&D”
Estimated investment
2003
USD$10,200
USD$1,000 Millions
2004
USD$13,500
2005
USD$15,200
General Electric Health Care (Reports 2005/2006)

27. 2008 Nuclear Magnetic Resonance Diagnosis market USD$1,900 Millions
Estimated Value of NMR Equipment market in the USA
USD$1,900 Millions
"Magnetic Resonance Imaging (MRI) Equipment: A Global Strategic Business Report“
Published by Global Industry Analysts, Inc.

28. World market for radiation Therapy equipment
Number of Companies
Estimated Average Production
Estimated selling price
Estimated market value 4
400
USD$4MM a
USD$7MM
USD$2 Billions
USD$2.8 Billions
Amersham Health (2004)

29. Annual expenditure in Treatment Total Annual Expenditure
HIV/Aids market
only for USA
Pacient Number
Annual expenditure in Treatment
Total Annual Expenditure
(MILLIONS)
1,000,000
USD$20,000

30. Contact Lázaro Eusebio Hernández Pérez
President and Legal Representative
for MRI-DT, S.A. de C.V.
Phone: 011 (52) (55)
Mobile phone: 011 (52) 1 (55)
Web page: